Upstream / Downstream
Explore pathways related to this product.
the purchase of 3 or more products
Find answers on our FAQs page.
- Additional protein information
- Analytical tools
IFN-γ (D3H2) XP® Rabbit mAb (PE Conjugate) #12274
This product is discontinued
Gallery: IFN-γ (D3H2) XP® Rabbit mAb (PE Conjugate) #12274
IFN-γ (D3H2) XP® Rabbit mAb (PE Conjugate) recognizes endogenous levels of total IFN-γ protein.
Monoclonal antibody is produced by immunizing animals with recombinant human IFN-γ protein.
This Cell Signaling Technology antibody is conjugated to phycoerythrin (PE) and tested in-house for direct flow cytometry analysis in human cells. The antibody is expected to exhibit the same species cross-reactivity as the unconjugated IFN-γ (D3H2) XP® Rabbit mAb #8455.
IFN-γ plays key roles in both the innate and adaptive immune response. IFN-γ activates the cytotoxic activity of innate immune cells, such as macrophages and NK cells (1,2). IFN-γ production by NK cells and antigen presenting cells (APCs) promotes the cell mediated adaptive immunity by inducing IFN-γ production by T lymphocytes, increasing class I and class II MHC expression, and enhancing peptide antigen presentation (1). The anti-viral activity of IFN-γ is due to its induction of PKR and other regulatory proteins. Binding of IFN-γ to the IFNGR1/IFNGR2 complex promotes dimerization of the receptor complexes to form the (IFNGR1/IFNGR2)2 -IFN-γ dimer. Binding induces a conformational change in receptor intracellular domains and signaling involves Jak1, Jak2, and Stat1 (3). The critical role of IFN-γ in amplification of immune surveillance and function is supported by increased susceptibility to pathogen infection by IFN-γ or IFNGR knockout mice and in humans with inactivating mutations in IFNGR1 or IFNGR2. IFN-γ also appears to have a role in atherosclerosis (4).
For Research Use Only. Not For Use In Diagnostic Procedures. Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc. XP is a registered trademark of Cell Signaling Technology, Inc.